Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 11.8% in December

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 20,200 shares, a decrease of 11.8% from the December 15th total of 22,900 shares. Based on an average daily trading volume, of 84,800 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the shares of the company are sold short.

Avalo Therapeutics Price Performance

Shares of AVTX stock traded up $0.02 during midday trading on Friday, reaching $6.75. 238,024 shares of the company traded hands, compared to its average volume of 129,572. The firm’s 50 day simple moving average is $9.29 and its two-hundred day simple moving average is $10.14. Avalo Therapeutics has a 1-year low of $4.00 and a 1-year high of $34.46.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AVTX. HC Wainwright started coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating on the stock. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently bought and sold shares of AVTX. Ikarian Capital LLC boosted its position in shares of Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics in the third quarter valued at about $9,186,000. Logos Global Management LP acquired a new stake in shares of Avalo Therapeutics in the second quarter valued at approximately $6,722,000. Finally, Affinity Asset Advisors LLC increased its stake in shares of Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after purchasing an additional 35,000 shares in the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.